All In Biotech

Free tool

FAERS Monitor: Multihance

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021357 or its brand name (Multihance, Gadobenate Dimeglumine). Reports on generic versions are filed under their own applications.

Reports

4,411

Serious

2,714

62% of reports

Hospitalization

778

Death reported

208

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pain623
  • nausea598
  • nephrogenic systemic fibrosis588
  • vomiting513
  • hypersensitivity437
  • urticaria426
  • anxiety384
  • dyspnoea356
  • injury356
  • emotional distress337
  • pruritus330
  • arthralgia293
  • burning sensation272
  • mobility decreased264
  • paraesthesia263

Reports by year received

View as table
YearReports
2005154
2006124
2007662
200854
2009196
2010245
2011295
2012135
2013181
2014249
2015181
2016203
2017225
2018229
2019359
2020344
2021133
202277
202382
202477
202563
2026143

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,748 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
nephrogenic systemic fibrosisSignal5881151.41057.5543,635
injurySignal35624.322.07,904
burning sensationSignal27218.616.54,500
mobility decreasedSignal26417.615.64,111
emotional distressSignal33713.312.03,835
urticariaSignal42612.211.14,373
hypersensitivitySignal43711.210.34,097
paraesthesiaSignal2638.07.11,609
anxietySignal3846.45.91,781
vomitingSignal5135.24.81,777
painSignal6234.84.51,949
pruritusSignal3304.13.7783
nauseaSignal5983.63.31,166
arthralgiaSignal2933.43.0493
dyspnoeaSignal3563.02.7485

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.